Switch to:
More From Other Websites
Hepatitis C researchers battle to 'nuke' the competition Jul 27 2014
Every Which Way But Short Jul 24 2014
[video] Cramer's Stop Trading: Yellen effect Jul 16 2014
A Pre-Earnings Update On Gilead Jul 10 2014
Seth Klarman Is Top-Performing Guru for First Half 2014 Jul 05 2014
A Primer On The Hepatitis C Market Jul 03 2014
Exclusive: Enanta Pharmaceuticals CEO Jay Luly Discusses Hep C Pipeline Jul 03 2014
Idenix (IDIX) is in Overbought Territory: What's Next? Jul 03 2014
What If Legacy Pharmaceutical And Consumer Business Keeps Falling For Merck? Jun 27 2014
Exclusive: Hepatitis C Stock Valuation With Enanta CEO Jay Luly Jun 27 2014
Keryx Biopharmaceuticals: Baupost Group's New Position Suggests A Possible Takeout And 100%+ Gains Jun 24 2014
Market Wrap For June 20: Yet Again, Dow And S&P 500 Indices Hit New Highs Jun 20 2014
[video] 3 Reasons for Russell 2000 surge Jun 20 2014
Achillion Could Win Idenix's Mystery Suitor: Analyst Jun 20 2014
Speculators On The Next HCV Acquisition Should Not Overlook Technological Platforms Jun 20 2014
Idenix received bid above $18.00 per share prior to deal with Merck Jun 20 2014
Merck begins tender offer to acquire Idenix Jun 20 2014
Idenix Pharmaceuticals Cut to Neutral from Buy at UBS Jun 19 2014
The Zacks Analyst Blog Highlights: Idenix, Achillion Pharmaceuticals, Nektar, Orexigen, Celgene,... Jun 19 2014


Add Notes, Comments or Ask Questions

User Comments

Bradlewski
ReplyBradlewski - 2 weeks ago
Merck is buying it for $24.5/share.


Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide